|Dr. Charles P. Theuer M.D., Ph.D.||CEO, Pres & Director||827.53k||N/A||1964|
|Mr. Scott B. Brown CPA, M.S.||Chief Financial Officer||459.21k||N/A||1981|
|Mr. Mark C. Wiggins M.B.A.||Chief Bus. Officer||506.25k||N/A||1956|
|Ms. Bonne Adams||Exec. VP of Clinical Operations||N/A||N/A||1977|
|Mr. Shahe Garabedian||Sr. VP & Head of Quality Assurance||N/A||N/A||N/A|
|Dr. James L. Freddo||Chief Medical Officer||N/A||N/A||1955|
|Mr. Ya Huang||Exec. Director of Statistical Programming||N/A||N/A||N/A|
|Dr. Brenda Marczi Pharm.D., Pharmd Mba||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
TRACON Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.